We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks.
Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis expert. He established the firm in 1979 and now has $299 billion in assets under management. Over the years, he has built a legacy of innovative investment strategies, a contrarian approach, and a focus on long-term growth.
Investment Philosophy and Strategies of Fisher:
Compared with many other firms, Fisher Investments’ most distinctive aspects are its methodical approach to portfolio management and its reliance on research. In his 1984 book Super Stocks, he popularized the Price-to-Sales (P/S) ratio to find undervalued growth stocks. The ratio continues to play a key role in his firm’s stock selection process, helping to uncover companies with strong growth prospects that might be hidden from the broader market.
Fisher’s contrarian mentality distinguishes him from most investors. He advises questioning mainstream market sentiments and looking for opportunities others might miss. His book The Only Three Questions That Count examines this more in-depth, explaining how good investors must constantly challenge their view of the world, find insights no one else sees, and combat mental biases to find the right investment opportunity.
Diversified Portfolio and Sector Emphasis:
The firm’s holdings express Fisher’s long-held maxim that diversification helps reduce risk. Technology is a particularly strong-performing sector, accounting for 31.8% of the portfolio as of Q3 2024, displaying Fisher’s faith in the enduring rise of tech stocks. The portfolio is also heavy in other sectors, such as services (14.6%), financial services (12.3%), and healthcare (10.5%).
In 2024, Fisher Investments achieved an incredible 32.18% return, fueled mainly by its tech positions, especially in companies that benefited from the artificial intelligence boom. While many investors have become cautious about frothy tech valuations, Fisher’s firm has remained steadfast, doubling down on AI chipmakers and other tech innovators.
Recent Developments:
In January 2025, Fisher Investments finalized the sale of a minority stake valued at nearly $3 billion to Advent International and the Abu Dhabi Investment Authority, valuing the firm at approximately $13 billion. The decision is a strategic move that has been a part of Ken Fisher’s long-term estate planning, allowing the firm to continue its private independence and never-ending commitment to outstanding client service. Given this, we will take a look at some of the best high growth stocks in Ken Fisher’s portfolio.
Our Methodology
To analyze Billionaire Ken Fisher’s Top 10 High Growth Stock Picks, we began by reviewing the largest positions in Fisher Asset Management’s portfolio as of Q3 2024. We focused on identifying stocks with trailing twelve-month (TTM) revenue growth of at least 20% compared to 2023, as this growth metric highlights companies demonstrating robust expansion. We then picked the first ten stocks that met the growth criteria, providing a clear overview of high-growth opportunities in the portfolio.
At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.
Novo Nordisk A/S (NYSE:NVO)
Net revenue growth in the past 12 months: 26.15%
Novo Nordisk A/S (NYSE:NVO), a global leader in healthcare specializing in treatments for chronic diseases like diabetes, obesity, hemophilia, and growth disorders, has recently faced market volatility. The company’s stock declined approximately 20% following clinical trial results for its obesity drug, CagriSema. The trial showed a weight reduction of 22.7%, slightly below the expected 25%, which caused investor concerns. Despite this temporary setback, the company remains well-positioned in its market.
In January 2025, Novo Nordisk (NYSE:NVO) expanded its partnership with Valo Health. This collaboration integrates human health data and AI technology to accelerate the development of new treatments for obesity, type 2 diabetes, and heart disease. Novo Nordisk committed $190 million in initial payments, with potential milestone-based payouts totaling up to $4.6 billion. This substantial investment highlights the company’s focus on innovation and addressing unmet needs in chronic disease management.
Analysts maintain a positive outlook on Novo Nordisk’s (NYSE:NVO) prospects. UBS Group recently upgraded its rating on the stock from “Sell” to “Buy,” citing confidence in the company’s strategic initiatives and market leadership. The continued investment in partnerships and product portfolio expansion reinforces the company’s resilience and growth potential.
Overall NVO ranks 6th on our list of Ken Fisher’s top high growth stock picks. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure: None. This article is originally published at Insider Monkey.
